Charlie Albright is Chief Scientific Officer at Editas Medicine. Charlie has more than 25 years of life sciences industry and academic leadership experience, most recently serving as Vice President of Genetically-Defined Diseases and Genomics at Bristol-Myers Squibb (BMS). Over his career, Charlie has led discovery programs that advanced investigational medicines into clinical development in a wide range of therapeutic areas, including neurodegeneration, pain, psychiatry, oncology and inflammation. Prior to his position as Vice President of Genetically-Defined Diseases and Genomics, he held multiple scientific leadership roles in neuroscience biology at BMS. Previously, he held positions at Incyte Corporation, DuPont Pharmaceuticals and Vanderbilt University School of Medicine. Charlie received a B.S. in Chemical Engineering and Ph.D. in Biology from the Massachusetts Institute of Technology (MIT). He was a postdoctoral fellow in the laboratory of Professor Robert Weinberg at the Whitehead Institute for Biomedical Research at MIT.
« Go Back